A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  title={A double-blind, delayed-start trial of rasagiline in Parkinson's disease.},
  author={C. Warren Olanow and Olivier Rascol and Robert A. Hauser and Paul D. Feigin and Joseph Jankovic and Anthony E. Lang and W. J. Langston and Eldad Melamed and Werner Poewe and Fabrizio Stocchi and Eduardo Tolosa},
  journal={The New England journal of medicine},
  volume={361 13},
BACKGROUND A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 mg or 2… 

Figures and Tables from this paper

Rapid onset of efficacy of rasagiline in early Parkinson's disease

Rasagiline had a rapid therapeutic effect from the first week of therapy, which further improved at 4 weeks, and the rapid onset of action and the absence of a dose titration are important issues in the management of the PD patient.

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease

Up to 52 weeks, rasagiline was well tolerated with sustained motor symptom improvement, supporting its use in Japanese patients with early PD.

Rapid onset of efficacy of rasagiline in early Parkinson’s disease

Rasagiline had a rapid therapeutic effect from the first week of therapy, which further improved at 4 weeks, and the rapid onset of action and the absence of a dose titration are important issues in the management of the PD patient.

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China

In levodopa-treated Chinese patients with Parkinson’s disease and motor fluctuations, adjunct rasagiline 1 mg/day statistically significantly reduced OFF time, and improved daily function and overall well-being, versus placebo.

Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Rasagiline is effective, safe, and well tolerated as monotherapy for the treatment of Chinese PD patients and an improvement trend was observed in the active treatment group for the subscales evaluation with parts II and III, while the difference to placebo was not statistically significant.

Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study

The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients.



A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Subjects treated with rasagiline, 2 and 1 mg/d, for 12 months showed less functional decline than subjects whose treatment was delayed for 6 months and the effects of early and later initiation of rasAgiline on progression of disability in patients with PD were compared.

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.

A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

  • C. OlanowR. Hauser O. Rascol
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2008
Positive results in a delayed start study indicate that patients who receive early treatment have a better outcome than those where the treatment is delayed, and the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial are described.

Timing of treatment initiation in Parkinson's disease: A need for reappraisal?

Clinical and imaging data both indicate that the early period after diagnosis is critical in terms of the rate of progression, implying that this is also a time of opportunity for interventions seeking to modify the course of the disease.

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

Deprenyl but not tocopherol delays the onset of disability associated with early, otherwise untreated Parkinson's disease and the action of deprenyl that accounts for its beneficial effects remains unclear.

The scientific basis for the current treatment of Parkinson's disease.

  • C. Olanow
  • Biology, Psychology
    Annual review of medicine
  • 2004
Insights into the organization of the basal ganglia in the normal and PD conditions has permitted the design of new treatment strategies that reduce the risk of developing motor complications and the development of putative neuroprotective drugs that might slow or stop disease progression.

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

Clinical trials aimed at detecting neuroprotection in Parkinson disease are reviewed and the controversies surrounding the interpretation of these studies are addressed.

Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

It is concluded that the most disabling long‐term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L‐dopa, and neuroprotective interventions in Parkinson’s disease should be judged by their ability to improve non‐L‐Dopa–responsive aspects of the disease.